Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference

Rhea-AI Summary

Geron Corporation (NASDAQ: GERN) announced that its Chairman and CEO, John A. Scarlett, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 28, 2022, at 11:00 a.m. ET. A live webcast of the presentation will be available on Geron's Investor Relations website and archived for 30 days after the event. Geron focuses on developing imetelstat, a first-in-class telomerase inhibitor, for treating hematologic malignancies, currently conducting two Phase 3 clinical trials: IMerge and IMpactMF.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on Friday, January 28, 2022 at 11:00 a.m. ET.

A live webcast of the presentation will be available through the Investor Relations section of Geron’s website under Events. Following the presentation, the webcast will be archived and available for replay for a period of 30 days.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005027/en/

Olivia Bloom

Chief Financial Officer

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

What is Geron Corporation's ticker symbol?

Geron Corporation's ticker symbol is GERN.

When is Geron Corporation participating in the investor conference?

Geron Corporation will participate in the B. Riley Securities Virtual Oncology Investor Conference on January 28, 2022.

Who is presenting for Geron Corporation at the investor conference?

John A. Scarlett, M.D., Chairman and CEO of Geron Corporation, will present at the investor conference.

How can I access the live webcast of Geron's presentation?

The live webcast will be available through the Investor Relations section of Geron's website.

What is the focus of Geron Corporation's clinical trials?

Geron Corporation's clinical trials focus on hematologic malignancies using imetelstat, a telomerase inhibitor.